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Abstract
Backgrounds: In recent years, low levels of Insulin-like Growth Factor-1 (IGF-1) have been suggested to be associated with higher 
risks of developing heart failure and higher long-term mortality rates following Acute Myocardial Infarction (AMI). However, the effect 
of IGF-1 levels on short-term survival has been rarely studied. In this study we aimed to assess any possible association between serum 
IGF-1 concentration following AMI and short-term survival rates.
Methods: In this study, serum total IGF-1 levels were measured in 56 patients within 24 hours following AMI and were compared to 
56 individuals with no cardiovascular disease. Patients were followed up to death or discharge from hospital (median = 6 days) and 
survival curves were compared based on median IGF-1 value.
Results: Mean (±SD) of serum IGF-1 levels were 232.73 ng/ml (±81.74) and 211.00 ng/ml (±58.22) in survived and expired patients 
respectively and the difference was not statistically significant (P value = 0.501). The difference between survival curves was also 
not statistically significant (P value = 0.246).
Conclusion: According to findings of this study, serum total IGF-1 concentration does not seem to be associated with short-term 
s urvival rates.
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Introduction
Insulin-like growth factor-1 (IGF-1) is involved in the 
growth and development of many cells,1–5 including 
cardiac myocyte.6 In addition, it has been found to 
interfere with apoptosis and cellular death in various 
tissues7–9 including myocardial cells.10,11 IGF-1 is syn-
thesized mainly by the liver and kidneys but also, in a 
paracrine and autocrine way, by endothelial and vas-
cular smooth muscle cells and by cardiac myocytes.1,2
In recent years, low levels of IGF-1 have been sug-
gested to increase the risk of developing cardiovas-
cular disease particularly myocardial infarction.12,13 
Moreover, data analyses based on Framingham and 
Rotterdam studies have reported low levels of IGF-1 
to be associated with the risk of developing heart 
failure.14,15 Further studies have emphasized the stim-
ulating effect of insulin like growth factors on left 
ventricular remodeling and long term survival fol-
lowing myocardial infarction.11,13,16,17
However, the effect of IGF-1 on short term sur-
vival in the acute phase of Acute Myocardial Infarc-
tion (AMI) has rarely been studied. The aim of this 
study was to evaluate serum IGF-1 levels following 
AMI and assess its possible association with short-
term  survival rates.
Methods
In this cross sectional analytic study from March 2008 
to July 2009, of 167 patients referred to the Coronary 
Care Unit of Rasoul Akram Hospital for management 
of suspected myocardial infarction, 111 patients were 
excluded (70 patients didn’t provide informed consent, 
15 had hypertension,10 had BMI . 30, 5 patients had 
acromegaly and 11 patients had chronic inflammatory 
disease). This left a study population with following 
inclusion criteria: age ,80 years, AMI diagnosed by 
WHO criteria and LVEF on admission .45%.
Subjects who were investigated as the control 
group had normal EKG without any history of chest 
pain or diabetes mellitus and were selected from 
patients admitted to Rasul Akram Hospital for oph-
thalmic problems. They did not consume any drugs 
which could interact with IGF-1.
All participants gave written informed  consent for 
inclusion in the study. The study protocol was approved 
by the Ethics Committee of the Iran  University of 
Medical Sciences (Tehran, Islamic Republic of Iran).
Blood sampling
A 5-ml blood sample was achieved from all patients 
within 24 hours of CCU admission, and centrifuged. 
Then serum was separated and sent for measurement 
of IGF-I. Concentration of IGF-1 was evaluated using 
radioimmunoassay. The normal range of this assay is 
107 ng/ml to 310 ng/ml. We also measured fasting blood 
sugar and lipid profile on the day after admission.
Patients were divided into low and high IGF-1 
groups, using median concentration of IGF-1 as the 
cut-point. All patients were followed until they were 
discharged from hospital or expired.
Statistical analyses
The Student’s T-test was used for comparison of IGF-1 
concentration between patients and control groups. 
Survival curves were constructed by the Kaplan-
Meier method and compared by log-rank test. Data 
are mean ± SD. P , 0.05 was considered significant. 
All tests were done with SPSS 16.0 ( Statistical Pack-
age for Social Sciences) for Microsoft Windows.
Results
A total of 56 patients with a mean (±SD) age of 58.53 
(±11.68) were enrolled to the study. Table 1 shows 
baseline characteristics of the MI affected group. 
Serum IGF-1 levels of 56 healthy controls aged 60.12 
(±6.16) was also measured as an estimate of normal 
IGF-1 values.
Comparing AMI affected patients and control 
group, mean (±SD) levels of serum IGF-1 were 
230.02 ± 79 ng/ml and 307.46 ± 64 ng/ml respec-
tively and the difference was statistically significant 
(P value , 0.001) (Fig. 1).
Among the patients, seven died of cardiovascu-
lar events. Three patients expired on the first day of 
admission, one on the second day, two on the third 
day and one on the fourth day. Table 2 compares a 
Table 1. Baseline characteristics of MI affected patients.
Age (±SD) 58.53 (±11.68)
Male/female 41/15
Diabetes 11 (19.6%)
hypertension 14 (25%)
hyperlipidemia 16 (28.6%)
ST-/non ST-elevation MI 45/11
LV ejection fraction (%) (±SD) 54.21 (±4.60)
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number of cardiovascular risk factors between this 
group and surviving patients, revealing statistical sig-
nificance for none of the variables.
No statistical significance could be found in 
the correlation between levels of IGF-1 and dura-
tion of hospitalization (P = 0.086). Mean IGF-1 
 levels were 232.73 ng/ml (±81.74) and 211.00 ng/ml 
(±58.22) in survived and expired patients respectively 
and the difference was not statistically significant 
(P value = 0.501).
Survival curves were constructed according to the 
median value of serum IGF-1 in the first 24 hours 
 following acute myocardial  infarction and are shown 
in Figure 2. The difference between curves was also 
not statistically significant (P value = 0.246).
Discussion
In this study, IGF-1 levels in the first 24 hours fol-
lowing acute myocardial infarction were found to 
be lower in the comparison with the control group. 
Event analysis was also performed to detect any pos-
sible difference of survival curves between higher 
and lower levels of IGF-1 while the analysis did not 
demonstrate a statistically significant distinction.
Table 2. Comparison of baseline characteristics between survivors and expired patients. 
survivors  
(n = 49)
expired patients  
(n = 7)
P value
Age (±SD) 58.04 ± 11.74 62 ± 11.57 0.407
Male/female 36/13 5/2 0.911
Diabetes 10 (20.4%) 1 (14.3%) 0.809
hypertension 12 (24.5%) 2 (28.6%) 0.820
Fasting Blood Sugar (FBS) 114.73 ± 34.89 117.66 ± 38.97 0.848
LDL (mmol/lit) 108.95 ± 40.07 108.83 ± 29.08 0.994
hDL (mmol/lit) 38.40 ± 10.45 39.50 ± 11.44 0.812
Tg (mmol/lit) 148.42 ± 74.97 128.33 ± 40.68 0.524
ST-/non ST-elevation MI 41/8 4/3 0.128
LV ejection fraction (±SD) 54.40 ± 4.60 52.85 ± 4.74 0.409
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Figure 1. Mean IgF-1 levels (ng/ml) in control and case groups.
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Previous studies have also documented a decrease 
in IGF-1 levels following MI.12,13,18 These reduced lev-
els have been shown to return to control level within 
one month and cytokine reactions are assumed to be 
responsible for this reduction.18 Besides these find-
ings, previous reports have also documented lower 
levels of IGF-1 to be associated with higher risks of 
developing heart failure and higher long term mortal-
ity rates following acute myocardial infarction.14–17
Unlike our study, a study published in 200818 reported 
significant difference in 90-day survival rates accord-
ing to the median value of IGF-1. As the sample size 
of the mentioned study and our study’s are very close 
to each other (54 and 56), sample size is very unlikely 
to be the cause of this mismatch. Instead, there is 
methodological difference between these two studies. 
The study followed patients for longer and reported 
90-day survival while we followed them up to the 
time of discharge. Thus it might be possible that the 
other study reports sub-acute survival instead of acute 
survival rates.
In conclusion, we did not detect any significant 
role for serum IGF-1 levels in short-term survival of 
MI affected patients in the acute phase of their dis-
ease. As there is disagreement between the results of 
this study and a previous study, addressing a similar 
question but with a different methodology and defi-
nition of short-time survival, further studies are sug-
gested to assess the compact of IGF-1 on short-term 
mortality rates in which the definition of “short-term” 
should be carefully determined.
Disclosure
This manuscript has been read and approved by all 
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Figure 2. Survival: long rank P value = 0.246.
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